Rontalizumab Biosimilar Monoclonal Antibody (IFN-α) for Research

Cat No.: GMP-Bios-ab-494

Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.、

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-494-1mg 1mg 618

Size: 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody
INN Name Rontalizumab
TargetIFNA1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesChugai Pharmaceutical;Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSystemic lupus erythematosus
Development Techna



About target - IFNA1

1. Protein Interferon alpha-1/13

2. Gene IFNA1

3. Organism Homo sapiens (Human)

Function
Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Miscellaneous
Interferons alpha-1 and alpha-13 have identical protein sequences.